ArticleInfection2024

Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study.

Wen Luo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.